Litigation Details for AbbVie Inc. v. Alkem Laboratories Limited (D. Del. 2022)
✉ Email this page to a colleague
AbbVie Inc. v. Alkem Laboratories Limited (D. Del. 2022)
| Docket | ⤷ Try a Trial | Date Filed | 2022-10-27 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Jennifer L. Hall |
| Jury Demand | None | Referred To | Jennifer L. Hall |
| Parties | HETERO LABS LIMITED | ||
| Patents | 10,537,572; 7,056,927; 7,176,211; 7,419,983 | ||
| Attorneys | Deirdre M. Wells | ||
| Firms | Heyman Enerio Gattuso & Hirzel LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in AbbVie Inc. v. Alkem Laboratories Limited
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for AbbVie Inc. v. Alkem Laboratories Limited (D. Del. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2022-10-27 | 12 | Patent/Trademark Report to Commissioner of Patents | ;7,176,211 B2 ;7,419,983 B2 ;10,537,572 B2 ;10,682,351 B2 ;11,344,551 B2. (vfm) (Entered: 10/28/2022)… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,056,927 B2 ;… 27 October 2022 1:22-cv-01423 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2023-10-04 | 133 | Order | Teva Pharmaceuticals, Inc. regarding U.S. Patents 10, 537,572, 10,682,351, and 11,344,551. Signed by Judge… 27 October 2022 1:22-cv-01423 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2023-12-01 | 163 | Notice of Service | Solco Healthcare US, LLC for U.S. Patent Nos. 11,542,239, 10,537,572, and 10,682,351; (4) Plaintiffs' …Contentions Against Alkem Laboratories Limited for U.S. Patent No. 11,542,239; (2) Plaintiffs' Initial Infringement…Labs Limited Unit-V, and Hetero USA Inc. for U.S. Patent No. 11,542,239; (3) Plaintiffs' Initial Infringement… Sun Pharmaceutical Industries Limited for U.S. Patent No. 11,542,239; and (5) Plaintiffs' Initial Infringement…Biophore India Pharmaceuticals Private Ltd. for U.S. Patent No. 11,542,239 filed by AbbVie Inc., AbbVie Ltd | External link to document |
| 2024-03-07 | 196 | Claim Construction Chart | phrases in U.S. Patent Nos. 7,419,983 (“the ’983 patent”), 10,537,572 (“the ’572 patent”), 10,682,351 …10,682,351 (“the ’351 patent”), and 11,542,239 (“the ’239 patent”).1, 2 The parties agree that no terms…the ’239 patent require construction. With respect to the ’572, ’351, and ’983 patents, the parties…351 Patent, Claim 1 elagolix sodium” ’572 Patent, Claims… ’572 patent, claim 1, 2 ’351 patent, claim 1 | External link to document |
| 2022-10-27 | 5 | ANDA Form | of U.S. Patent No. 10,537,572: September 1, 2036 Date of Expiration of U.S. Patent No. 10,682,351… 2026 *The patent applicant has applied for extension of patent term of the ’927 patent under 35 U.S.C…extension. **The patent applicant has applied for extension of patent term of the ’983 patent under 35 U.S.C… of U.S. Patent No. 7,056,927: September 10, 2024* Date of Expiration of U.S. Patent No. 7,419,983…Accordingly, the ’927 patent will expire on September 10, 2029, if granted the 1,826 days of patent term extension | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
